TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Flow Nasal Cannula Versus Nasal Intermittent Mandatory Ventilation for Respiratory Distress Syndrome: a Randomized, Controlled, Prospective Study
Brief Summary: The investigators hypothesize that while the extremely low birthweight (ELBW) infants (\<1000 g) may need NIMV for the treatment of RDS, larger infants or the smaller ones post extubation may enjoy the comfort benefits associated with HFNC while getting coparable respiratory support to NIMV.


Options:
A: Inclusion Criteria:

* birthweight 500 to 1250 grams
* postnatal age day 1 to day 10
* infant considered a candidate for methylxanthine therapy by clinical staff

Exclusion Criteria:

* dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* unlikely to comply with long-term follow-up
* prior treatment with a methylxanthine
B: Inclusion Criteria:

1. Gestational age between 24 to 34 and 6/7 weeks assessed by the obstetrical team from dating of last menstural period or ultrasound and weight \>1000 g for the initial treatment of RDS or \<35 weeks post extubation or for apnea of prematurity
2. Infants with RDS who will need NRS as initial therapy or after extubation and for apnea of prematurity, 3. written informed consent.

Exclusion Criteria:

1. Significant morbidity apart from RDS including: cardiac disease (not including patent ductus arteriosus \[PDA\]), congenital malformation, or if they had cardiovascular or respiratory instability because of sepsis, anemia or severe intraventricular hemorrhage (IVH),
2. Parents refuse consent.
3. Unavailability of suitable ventilator.
C: Inclusion Criteria:

* Infants \</= 1250 grams who are going to be extubated

Exclusion Criteria:

* Congenital abnormalities of the upper airway
* Acquired nasal septum injury
* Congenital Heart Disease excluding Patent Ductus arteriosus
D: Inclusion Criteria:

* Birth weight \<1000 gm
* Gestational age \<30 completed weeks
* Intention to manage the infant with non-invasive respiratory support (i.e. no endotracheal tube), where either:

  * the infant is within the first 7 days of life and has never been intubated or has received less than 24 hours of total cumulative intubated respiratory support;
  * the infant is within the first 28 days of life, has been managed with intubated respiratory support for 24 hours or more and is a candidate for extubation followed by non-invasive respiratory support.

Exclusion Criteria:

* Considered non-viable by clinician (decision not to administer effective therapies)
* Life-threatening congenital abnormalities including congenital heart disease (excluding patent ductus arteriosis)
* Infants known to require surgical treatment
* Abnormalities of the upper and lower airways
* Neuromuscular disorders
* Infants who are \>28 days old and continue to require mechanical ventilation with an endotracheal tube

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Ultrasound Guidance for Radial Arterial Blood Sampling
Brief Summary: The investigators aim to determine if ultrasound guidance results in improved technique when drawing blood via a radial artery puncture.


Options:
A: Inclusion Criteria:

* Age over 18 years;
* Hospitalization in resuscitation;
* Necessity of installation of an arterial catheter
* Signed informed consent.
* Affiliation to a social security scheme

Exclusion Criteria:

* Patient under tutorship or curatorship
* Minor Patient
B: Inclusion Criteria:

* all patients with clear indication to radial artery catheterization like hemodynamic instability or the need of frequent arterial samples

Exclusion Criteria:

* refusal, Peripheral arterial diseases
C: Inclusion Criteria:

* The subject has signed consent
* The subject is affiliated with a social security system
* Health status necessitates an arterial blood sample for diagnostic, prognostic or therapeutic reasons

Exclusion Criteria:

* The subject is participating in another study
* The subject is in a study exclusion period determined by a previous study
* The subject is under guardianship
* The subject refuses to sign consent
* Impossible to correctly inform the patient
* The patient is pregnant, breastfeeding, or parturient
* Allergies to one or more of the following: methyl, propylbenzoate, propylene glycol, chlorhexidine gluconate
* Contraindication for an arterial puncture (at the radial artery)
* Cardio-respiratory arrest
D: Inclusion Criteria:

1. Age ≥ 18 years.
2. The distal and proximal radial artery must be palpable and non-occlusive flow must be confirmed by (Doppler) ultrasound.
3. Patient should be able to comply with the protocol.
4. Provide written informed consent before study participation

Exclusion Criteria:

1. Obligatory femoral or forearm radial access
2. Previous ipsilateral forearm radial artery occlusion.
3. Patient on therapeutic oral anticoagulation.
4. Very large hand/wrist anatomy that will preclude using the available hemostatic radial bands.
5. Enrolment in another study that competes or interferes with this study.
6. Poor clinical condition like cardiogenic shock, which prohibits pre- and post-procedural function tests.
7. Subject with planned complex PCI or procedure necessitating multiple intervention.
8. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.
9. History of stroke with residual deficit that affects hand function.
10. Previous radial artery catheterization within 1 year.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Ultrasound Guidance for Radial Arterial Blood Sampling
Brief Summary: The investigators aim to determine if ultrasound guidance results in improved technique when drawing blood via a radial artery puncture.


Options:
A: Inclusion Criteria:

* Age above 18 years old.
* Scheduled for selective surgery.
* Requirement of perioperative vascular puncture and catheterization.
* American standard of anesthesia level I-IV.

Exclusion Criteria:

* Contraindication to vascular puncture or catheterization.
* Occlusion or thrombosis of target vessel evaluated by ultrasound.
* Refuse or disagreement from participants.
B: Inclusion Criteria:

* all patients with clear indication to radial artery catheterization like hemodynamic instability or the need of frequent arterial samples

Exclusion Criteria:

* refusal, Peripheral arterial diseases
C: Inclusion Criteria:

* The subject has signed consent
* The subject is affiliated with a social security system
* Health status necessitates an arterial blood sample for diagnostic, prognostic or therapeutic reasons

Exclusion Criteria:

* The subject is participating in another study
* The subject is in a study exclusion period determined by a previous study
* The subject is under guardianship
* The subject refuses to sign consent
* Impossible to correctly inform the patient
* The patient is pregnant, breastfeeding, or parturient
* Allergies to one or more of the following: methyl, propylbenzoate, propylene glycol, chlorhexidine gluconate
* Contraindication for an arterial puncture (at the radial artery)
* Cardio-respiratory arrest
D: Inclusion Criteria:

* Surgery under general anesthesia
* Requires invasive arterial blood pressure monitoring

Exclusion Criteria:

* Infection/hematoma/skin disease/arteriovenous fistula/recent catheterization scar in radial artery or posterior tibial artery
* Peripheral vascular disease
* Congenital aortic disease

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Ultrasound Guidance for Radial Arterial Blood Sampling
Brief Summary: The investigators aim to determine if ultrasound guidance results in improved technique when drawing blood via a radial artery puncture.


Options:
A: Inclusion Criteria:

* All surgical intensive care unit patients at Yale New Haven Hospital in whom the indication for arterial catheterization has been established by the attending physician will be eligible for consented randomization to either the "Palpation" or the "Ultrasound" group.

Exclusion Criteria:

* The patient or his/her surrogate declines to participate or the patient lacks a radial artery into which a catheter can be place.
B: Inclusion Criteria:

* Patient admitted or treated in the acute emergency department
* Indication for a arterial blood gas analysis, according to the physician responsible for the patient's hospital stay / treatment

Exclusion Criteria:

* Patient age \< 16 years
C: Inclusion Criteria:

* Undergoing vessel catheterization
* Able to give written informed consent

Exclusion Criteria:

* Unable to give informed consent
* Prisoners, pregnant women, and children
D: Inclusion Criteria:

* The subject has signed consent
* The subject is affiliated with a social security system
* Health status necessitates an arterial blood sample for diagnostic, prognostic or therapeutic reasons

Exclusion Criteria:

* The subject is participating in another study
* The subject is in a study exclusion period determined by a previous study
* The subject is under guardianship
* The subject refuses to sign consent
* Impossible to correctly inform the patient
* The patient is pregnant, breastfeeding, or parturient
* Allergies to one or more of the following: methyl, propylbenzoate, propylene glycol, chlorhexidine gluconate
* Contraindication for an arterial puncture (at the radial artery)
* Cardio-respiratory arrest

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cost Effectiveness of Building Capacity of Mid-level Practitioners in Sub-Saharan Africa for the Care and Prevention of HIV, Tuberculosis, Malaria and Related Infectious Diseases
Brief Summary: This evaluation aim is to investigate a cost-effective way to build capacity for the care and prevention of infectious diseases among mid-level practitioners (MLP) in sub-Saharan Africa. Classroom based training continues to be the dominant form of training, despite evidence that suggests that on-site support (OSS) is more beneficial. Definitive evidence that on-site support is the most effective way to deliver the required outputs and related outcomes is still lacking. IDCAP will provide two interventions that integrate training in TB, HIV/AIDS and malaria as well as other infectious diseases, and the effects will be studied: 1) Integrated Management of Infectious Disease (IMID) training program for individual MLP, and 2) On-site support (OSS) for team of health professionals. This study employs a mixed design with pre/post and cluster randomized trial components. Interventions are at the level of the individual participant for IMID and at the level of the site (health facility) for OSS. All participants attend a 3-week course, followed by two 1-week booster courses over a six month period. After the 3-week course, a randomized arm of half the sampled facilities also received OSS every month for 9 months and bi-monthly for 6 additional months.


Options:
A: Inclusion Criteria:

Facilities selected for OSS:

* The health facility had to be a HC IV or comparable facility such as a small general hospital or non-governmental organization clinic
* It had to be an active ART site or accredited ART site that is scheduled to become active by April 2009
* No past or current participation in a partnership with the U.S. Department of Defense
* Has a population of potential patients who are not prisoners
* Representation from all six administrative regions of Uganda

Exclusion Criteria:

* NA

MLP selected from the participating facilities for IMID:

Two mid-level practitioners (clinical officers, nurses, or midwives) who are actively engaged in clinical infectious-disease care will be selected for enrollment in IMID
B: Inclusion Criteria:

* Internal medicine residents (Mayo-Rochester campus)
C: Inclusion Criteria:

* people aged 75 years or older

Exclusion Criteria:

* people aged 75 years or older
* refusal of consent to participate
* a life expectancy of less than 6 months
D: Inclusion Criteria:

* Working at the A\&E department of the UMC-Utrecht.

Exclusion Criteria:

* Absent during one of the two measurement periods.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty
Brief Summary: The purpose of this study is to determine whether Adductor-Canal-Blockade is effective at reducing pain and morphine consumption after revision knee arthroplasty.


Options:
A: Inclusion Criteria:

* Revision Knee Arthroplasty in general anaesthesia
* American society of anesthesiologists (ASA) 1-3
* BMI 18-40
* Written informed consent

Exclusion Criteria:

* Can not cooperate to the exam
* Do not speak or understand Danish
* Drug allergy
* Alcohol or drug abuse
B: Inclusion Criteria:

* Total Knee Arthroplasty in general anaesthesia
* ASA 1-3
* BMI 18-40
* Written informed consent

Exclusion Criteria:

* Can not cooperate to the exam
* Do not speak or understand Danish
* Drug allergy
* Alcohol or drug abuse
* Daily consumption of strong opioids
C: Inclusion Criteria:

* written informed consent
* ASA 1
* BMI \> 18 og \< 25

Exclusion Criteria:

* Can not cooperate to the exam
* Do not speak or understand Danish
* Drug allergy
* Alcohol or drug abuse
* Daily consumption of analgetics on prescription
* Any drug intake within the last 48 hours
* Neuromuscular defects in the femoral nere, the obturator nerve or the muscles of the thigh.
* Previous surgery or trauma to the lower limb
* Diabetes Mellitus
* Intake of steroids, except steroids for inhalation
* Physical exercise within the last 24 hours prior to Day 1 and 2 of the study
D: Inclusion Criteria:

* ASA 1-3
* BMI \> 18 og \< 40
* total knee arthroplasty in spinal anesthesia

Exclusion Criteria:

* Can not cooperate to the exam
* Do not speak or understand Danish
* Drug allergy
* Alcohol or drug abuse
* Daily consumption of strong opioids
* Rheumatoid arthritis
* Intake of glucocorticoids
* Effect of spinal anesthesia stopped prior to performing the regional block

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents
Brief Summary: The purpose of this study is to assess whether the daily addition of a protein-rich breakfast leads to beneficial changes in appetite control, food intake regulation,and cognitive function in overweight \& obese 'breakfast skipping' young women.


Options:
A: Inclusion Criteria:

* All six full-time schools with the program called Programa Saúde na Escola in Fortaleza were eligible
* students of both sexes
* students aged 12-15 years
* students who are enrolled in 7-9 grade classes

Exclusion Criteria:

* students who are younger than 12 years-old and older than 15 years-old
* students with uncompleted data at baseline or 4-months follow-up
* students who are absence in the school days with data collection
* students who dropout the school
* students who refused to participate in data collection or intervention
B: Inclusion Criteria:

* Healthy kindergarten children

Exclusion Criteria:

* Children with severe chronic disease (restricting physical activity)
C: Inclusion Criteria:

The participants must meet the following inclusion criteria:

* Female
* Age range 15-20 y
* Overweight to obese (85th -99th percentile for BMI for age; BMI: 25-39.9 kg/m2
* No metabolic, psychological, or neurological diseases/conditions
* Not currently/previously on a weight loss/other special diet
* Frequently eats lunch ( ≥ 5 eating occasions/wk)
* Consistently skips breakfast every week day (i.e., 5 week days/week)
* Right-handed (necessary for the fMRI analyses)

Exclusion Criteria:

The participants will be excluded from participation in the study if they meet the following exclusion criteria:

* Male
* Age \>20 y and \<15 y
* Under Weight (\<5th percentile for BMI for age; BMI: \<18 kg/m2)
* Normal Weight (6th-84th percentile for BMI for age; BMI: 18-24.0 kg/m2)
* Morbidly Obese (BMI: \>40 kg/m2)
* Clinically diagnosed with diabetes (Type I or Type II), having an eating disorder, or having any other metabolic, psychological, or neurological diseases/conditions that would influence the study outcomes.
* Not currently/previously on a weight loss or other special diet (in the past 6 months)
* Skip lunch ( ≥ 2 eating occasions/wk)
* Consume breakfast (≥ 2 eating occasions/wk)
* Left-handed
* Claustrophobic (≥ 2 past bouts of claustrophobia when exposure to small spaces)
* Do not meet the fMRI criteria established by the MU-BIC (regarding metal implants, etc.)
* Pregnant
D: Inclusion Criteria:

* All children in 3-5 grades who provide parental consent and child assent will be eligible to participate in the project.

Exclusion Criteria:

* Participants who meet the following exclusion criteria will not be considered for participation.
* Do not provide consent
* unable or unwilling to adhere to project procedures

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Intestinal Helminths on Gut Microflora
Brief Summary: Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.


Options:
A: Inclusion Criteria:

* Subject, male or female, is 5-14 years of age
* Subject is otherwise in an healthy condition (medical history and physical examination)
* Parent(s)/guardians of subjects (or their legally-accepted representatives) signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study.
* Subject of ≥6 years has assented (agreed) to participate in the study.
* Subject of ≥12 has signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
* The subject swallowed the entire drug (ALB 400 mg) under supervision
* Subject provides a stool sample of at least 9 grams

Exclusion Criteria:

* Subject has active diarrhea (defined as the passage of 3 or more loose or liquid stools per day) at baseline or follow-up
* Subject has any acute medical condition or is experiencing a severe concurrent medical condition
* Subject has a known hypersensitivity to benzimidazole drugs
* Subject has received an anthelminthic treatment within 90 of the start of the treatment.
* Subject vomited within 4 hours after drug administration
* Subject is unable to provide a stool sample at follow-up
B: Inclusion Criteria:

* Subjects with a diagnosis of CL based on the presence of typical skin lesions and a positive Montenegro skin test
* Evidence of helminthic infection by parasitological examination of first stool sample
* Males or females between 13 and 50 years of age
* Maximum of 3 ulcers with no more than 2 body regions involved
* Period of 15 to 60 days from the onset of the first ulcer
* Subject agreement to follow-up visits and therapy
* Ability to give informed consent

Exclusion Criteria:

* Pregnancy
* Breastfeeding mothers
* Presence of mucosal disease
* History of prior treatment with antimonial drugs.
* History of prior treatment with anthelminthic drugs within the last 6 months.
* History of allergy to pentavalent antimony or antihelminthic
* Presence of underlying disease which affects the immune response, such as HIV and diabetes mellitus
C: Inclusion Criteria:

* Children should be infected with a minimum of 150 eggs/gram of any of the three species of STH (i.e. Ascaris or hookworms or Trichuris).

Exclusion Criteria:

* Not willing to participate
* Unable to give samples for follow up
* Severe intercurrent medical condition
* Diarrhoea at first sampling
D: Inclusion Criteria:

* presence of intestinal helminths eggs in the stool

Exclusion Criteria:

* allergy to imidazole derivate
* No intestinal helminths

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Introducing Rapid Diagnostic Tests Into the Private Health Sector in Uganda: a Randomised Trial Among Registered Drug Shops to Evaluate Impact on Antimalarial Drug Use
Brief Summary: Most malaria deaths occur within 48 hours of onset of symptoms, and in rural areas with poor access to health facilities, home management of malaria (HMM) can improve the timeliness of treatment and reduce malaria mortality by up to 50%. In order to maximize both coverage and impact, artemisinin combination therapies (ACTs) should be deployed in HMM programmes, as well as in formal health facilities. Up to 80% of malaria cases are treated outside the formal health sector and shops are frequently visited as the first (and in some cases only) source of treatment. Strategies to deploy ACTs in Africa thus also need to examine the role of shops in home management and to ensure that drugs sold are appropriate. The current practice of presumptive treatment of any febrile illness as malaria (both at health facilities and in the context of HMM) based solely on clinical symptoms without routine laboratory confirmation, results in significant over-use of antimalarial drugs. With ACT being a more costly regimen, it is important to be more restrictive in its administration and rapid diagnostic tests (RDTs) provide a simple means of confirming malaria diagnosis in remote locations lacking electricity and qualified health staff.

This study therefore proposes to evaluate the feasibility, acceptability, and cost-effectiveness of using RDTs to improve malaria diagnosis and treatment by ocal drug shops in an area with high malaria transmission.


Options:
A: Inclusion Criteria:

* Any patient where the CHW\* or clinician considers malaria in the diagnosis - either prescribing an antimalarial or would request a malaria test if available or referring for diagnosis of malaria elsewhere.

  \* \*any community health worker who consults with patients and prescribes treatment, and is administratively attached to one of the study clinics.
* Patient, or parent/guardian, gives informed consent to the study.

Exclusion Criteria:

* Patients with a diagnostic result from another facility.
* Patients referred on for diagnosis in the private sector.
* Patients who have signs of severe or complicated disease and are referred prior to giving any diagnosis using the interventions.
B: Inclusion Criteria:

* living in one of the study cluster (villages)
* no story of allergy to any of the study drugs
* history of fever or body temperature \>= 38.5°C

Exclusion Criteria:

* signs of severity/complications like impaired consciousness, convulsions, fast breathing etc
C: Inclusion Criteria:

* Patients with fever
* uncomplicted malaria

Exclusion Criteria:

* Complicated malaria
* known allergic reactions to Lumartem
D: Inclusion Criteria:

* Patients reporting to chemical seller with complaint of fever or who request for an anti-malarial drug

Exclusion Criteria:

* Clients providing a prescription from a health facility
* Clients with signs of severe disease who will be referred onward

Answer: C